Using Mounjaro After 30 Days: What to Expect as Treatment Continues

You've finished your first pen. Here's what happens at day 30.

Picture this: your first Mounjaro pen is nearly done, the nausea that hit hardest around week two has eased off, and you're starting to notice your appetite sitting differently than it used to. That's a normal landmark. The first four weeks are calibration. Most people tolerate 2.5mg without severe side effects; some barely notice anything at all, which can feel anticlimactic. The prescriber reviewing your repeat isn't expecting dramatic results at this stage, they're checking you've handled the medicine safely and are ready to move forward.

At the 30-day mark, a clinical review is required before any further supply. At nume, a GPhC-registered prescriber reads through your update personally, no automated decision-making. You'll typically be asked about tolerability, any side effects, and whether your circumstances have changed. If everything looks right, the 5mg dose is the usual next step. If side effects were significant, staying at 2.5mg for another four weeks is a reasonable clinical choice. The NHS tirzepatide page confirms this graduated approach as standard practice.

A note on timing: if your review falls over a bank holiday or you ordered mid-month around payday, factor in delivery windows. Ordering your repeat before the pen runs out (rather than the morning after) keeps your treatment uninterrupted, and understanding what happens with Mounjaro after 30 days can help you plan that handover moment with confidence. Gaps between doses aren't ideal; your prescriber can advise if one occurs.

What you'll likely notice between months one and three

The clinical trial data for tirzepatide (the SURMOUNT-1 study published in the New England Journal of Medicine) showed that meaningful weight loss typically accelerates through months two and three as doses increase. The 20% or so average reduction seen by the end of the 72-week trial was built gradually, not front-loaded into the first month. Expecting dramatic results at day 30 sets the wrong clock.

What most people do notice early on is a change in hunger signals. Meals feel filling sooner. The urge to eat between meals is quieter. Some describe thinking about food less. These shifts are real and driven by how tirzepatide slows gastric emptying and affects the appetite centres in the brain. They tend to become more pronounced after the 5mg increase, and again at 7.5mg.

Side effects can briefly resurface with each dose step, a few days of nausea, softer stools, or feeling full to the point of discomfort. This usually settles within a week. Staying well hydrated, eating smaller portions of protein-rich food, and avoiding fatty or very rich meals helps. None of this replaces guidance from your prescriber, but it is consistent with what the evidence and standard clinical practice recommend alongside treatment.

If you're curious about what treatment costs look like as you continue, the Mounjaro pricing page sets out how monthly costs are structured for private patients in the UK.

Questions to ask before your month-two pen arrives

The 30-day review is also a natural moment to raise anything that didn't feel right in the first pen. Side effects that are manageable but annoying, questions about injection technique, uncertainty about what counts as a reason to contact your prescriber urgently, all fair game.

A few questions worth having ready. Are you losing weight at a rate that suggests the dose is working? Have you had any pain in your upper abdomen that spreads to the back? That particular symptom (persistent, severe stomach pain that radiates) is one the MHRA flagged in its January 2026 Drug Safety Update on GLP-1 medicines as a sign to seek medical help promptly, given the known (though infrequent) risk of pancreatitis. It's not something to monitor at home. Report suspected side effects through the MHRA Yellow Card scheme, and if you've noticed any unusual hearing changes, it's worth reading about the reported link between Mounjaro and tinnitus so you know what to mention to your prescriber.

Also worth considering at this stage: if you started Mounjaro while taking an oral contraceptive pill, your prescriber should have advised adding a non-oral method for the first four weeks of each dose increase, since tirzepatide can reduce how well the pill is absorbed. The detailed clinical guidance on continuing treatment covers this and other interaction points, and the practical guidance on taking Mounjaro after 30 days walks through what the ongoing routine looks like from your second pen onwards.

For more on the broader treatment landscape and how Mounjaro fits into it, the weight-loss treatment overview is a useful reference. And if you have general questions about the process, the FAQs page covers the most common ones our prescribers hear.

If you're thinking about starting treatment or reviewing whether Mounjaro is still the right fit, check your eligibility with a free consultation, a prescriber will review your situation the same day.